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Differential DNA methylation of the hypothalamic-pituitary-adrenal axis related gene FKBP5
has recently been shown to be associated with varying response to environmental influences
and may play a role in how well people respond to psychological treatments. Participants
(n = 111) received exposure-based cognitive behavioural therapy (CBT) for agoraphobia with or
without panic disorder, or specific phobias. Percentage DNA methylation levels were measured
for the promoter region and intron 7 of FKBP5. The association between percentage reduction
in clinical severity and change in DNA methylation was tested using linear mixed models. The
effect of genotype (rs1360780) was tested by the inclusion of an interaction term. The associa-
tion between change in DNA methylation and FKBP5 expression was examined. Change in per-
centage DNA methylation at one CpG site of intron 7 was associated with percentage reduction
in severity (β = −4.26, p = 3.90 × 10−4), where a decrease in DNA methylation was associated
with greater response to therapy. An interaction was detected between rs1360780 and changes
in DNA methylation in the promoter region of FKBP5 on treatment outcome (p = .045) but did
not survive correction for multiple testing. Changes in DNA methylation were not associated
with FKBP5 expression. Decreasing DNA methylation at one CpG site of intron 7 of FKBP5 was
strongly associated with decreasing anxiety severity following exposure-based CBT. In addition,
there was suggestive evidence that allele-specific methylation at the promoter region may also
be associated with treatment response. The results of this study add to the growing literature
demonstrating the role of biological processes such as DNA methylation in response to environ-
mental influences.
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1 | INTRODUCTION
Research examining genetic and biological factors involved in response
to psychological therapies has gained momentum in recent years. A
number of studies have identified candidate gene predictors of therapy
response, although results are inconsistent and have been of small
effect (Lester & Eley, 2013). Identification of the potential biological
mechanisms of response has led researchers to explore the epigenetic
process of DNA methylation. Early studies in this area have demon-
strated that changes in DNA methylation may underlie response to
psychological therapies (e.g., Perroud et al., 2013; Roberts et al., 2014;
Ziegler et al., 2016). Of particular relevance for the current study,
changes in DNA methylation at the promoter region of FKBP5 have
also been implicated in response to exposure therapy in veterans with
post-traumatic stress disorder (PTSD) (Yehuda et al., 2013), with
decreases in region-specific DNA methylation across the course of*Authors contributed equally to the work.
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therapy associated with better response and increases with poorer
response. In addition, we previously reported allele-specific changes
in FKBP5 promoter methylation were associated with response
to Cognitive Behavioural Therapy (CBT) in children with anxiety dis-
orders (Roberts et al., 2015). Specifically, a better response to ther-
apy was associated with a decrease in DNA methylation, but only in
individuals with FKBP5 risk genotypes.
FKBP5 plays a critical role in reactivity to stress through nega-
tive regulation of the hypothalamus-pituitary-adrenal (HPA) axis.
Stress exposure rapidly stimulates glucocorticoid secretion and ter-
mination of this response involves binding of glucocorticoids such
as cortisol at the glucocorticoid receptor. FKBP5 acts as a func-
tional negative regulator of glucocorticoid receptor sensitivity by
reducing binding affinity and restricting nuclear translocation
(Denny, Valentine, Reynolds, Smith, & Scammell, 2000; Wochnik
et al., 2005). An ultra-short negative feedback loop is created by
the regulation of FKBP5 mRNA expression by glucocorticoids via
glucocorticoid response elements. Dysregulation of this process
has been widely implicated in stress related disorders such as anxi-
ety disorders (Binder, 2009; Holsboer, 2000; Pariante &
Miller, 2001).
Studies of FKBP5 show support for an interaction between
negative/stressful environments and genotype (including the SNP
rs1360780) predicting adverse mental health outcomes, such as
PTSD, depression and suicidality (Appel et al., 2011; Binder et al.,
2008; Koenen et al., 2005; Roy, Gorodetsky, Yuan, Goldman, &
Enoch, 2010; Zimmermann et al., 2011). Further research investi-
gating the potential mechanism underlying this gene-by-
environment interaction has identified allele-specific DNA methyla-
tion patterns following childhood trauma (Klengel et al., 2013). It is
thought that this association is facilitated by genotype-dependent
structural differences, leading to functional alterations in the
responsiveness of FKBP5 to glucocorticoid receptor activation. The
involvement of FKBP5 methylation in response to both positive
environments (e.g., psychological therapy, Roberts et al., 2015;
Yehuda et al., 2013) and negative environments (e.g., childhood
trauma, Klengel et al., 2013) suggests that epigenetic variation in
this gene may represent a marker of differential susceptibility –
that is, sensitivity to the environment “for better or for worse”
(Belsky et al., 2009).
In this study, we examined the association between changes in
DNA methylation in two regions of FKBP5 and therapy outcome at
posttreatment and follow-up in a sample of adults (n = 111) with fear-
related anxiety diagnoses receiving exposure-based CBT. In addition,
we utilized genetic data (FKBP5 SNP rs1360780) to test for allele-
specific effects of DNA methylation changes. This study explores
response to a psychological therapy across the whole treatment
period, and builds on previous research demonstrating that epigenetic
changes in FKBP5 may play a role in treatment response (Roberts
et al., 2015; Yehuda et al., 2013). It is the first study that examines
DNA methylation changes at intron 7 of FKBP5 with respect to psy-
chological therapy response, and the first to combine genetic, epige-
netic and gene expression data.
2 | METHODS
2.1 | Sample & treatment
Participants (n = 111) were recruited at Mental Health Research and
Treatment Center, Ruhr-Universität Bochum, Germany (n = 61,
55.0%) or the Dental Clinic Bochum, Germany (n = 50, 45.0%). Age at
baseline ranged from 19 to 68 years (mean = 39.9 years), and 67.3%
of the sample were female. All participants were treated for agorapho-
bia with or without panic disorder (n = 34, 30.6%) or specific phobia
(n = 77, 69.4%; including dental fear – n = 50, 45.0% of total). The full
study sample reported here includes participants with these fear-
related anxiety disorders as exposure is a key element of treatment
for such diagnoses. Diagnoses were made according to DSM-IV cri-
teria by trained clinicians using the Diagnostisches Interview bei Psy-
chischen Störungen (DIPS) and mini-DIPS (Margraf, 1994; Margraf,
Schneider, & Ehlers, 2013; Schneider & Margraf, 2011). At pretreat-
ment, 33.3% (n = 37) were smokers, 6.3% (n = 7) were using a form of
psychoactive medication, and 33.3% (n = 37) took other regular
medications.
All participants completed one of four exposure therapy or
exposure-based CBT treatment programs as detailed below and
shown in Supporting Information Figure S1. Exclusion criteria included
psychotic symptoms and presence of severe learning difficulties.
Treatment was administered at the Mental Health Research and
Treatment Centre in three groups. All participants received five pre-
liminary sessions covering diagnosis and psychoeducation before
starting therapy. Participants with a primary diagnosis of panic disor-
der were randomized either to exposure-based CBT (n = 17) or to an
exposure-alone condition without any element of cognitive restruc-
turing (n = 17) [Clinical Trials: NCT01680327]. Participants with spe-
cific phobia (not primarily associated with dental fear, n = 27) were
treated in a program of up to 25 sessions of in vivo exposure. Partici-
pants in these groups were excluded if they were using anxiolytic
medication. Individuals with high levels of dental fear (n = 50) were
treated in a dental anxiety-specific program at the Dental Clinic
Bochum. Treatment was given in five sessions, including an initial
diagnostic and psychoeducation session, and a session developing
relaxation techniques and focusing on helpful thoughts. These coping
strategies were then encouraged in three sessions of consisting of
exposure scenarios such as video exposure, noise exposure and in
sensu exposure (virtual reality or visualization). Concurrent psychoac-
tive medication was not an exclusion criterion.
2.2 | Outcome measures
Treatment response was defined as change in clinician rated sever-
ity of the treated diagnosis, as determined using the Clinical Global
Impression – Severity (CGI-S) scale. The CGI-S consists of a scale of
1–7, with a score of 1 indicating that the patient is healthy, and
7 indicating that that the patient is extremely ill. Scores were trans-
posed to a scale of 0–6, and percentage improvement from pre
to post-treatment and pretreatment to follow-up was calculated
for all participants. The mean number of days from pre- to post-
treatment was 229.9 (SD: 201.8; range: 19–736). The mean interval
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from post-treatment to follow-up was 219.1 (SD: 74.1; range:
87–640).
2.3 | Sample collection and extraction
Whole blood samples were drawn using EDTA tubes at pretreatment,
posttreatment, and follow-up (usually 6 months following the con-
clusion of treatment; mean 219 days). DNA was extracted using the
FlexiGene DNA kit (Qiagen, Hilden, Germany). Extracted samples
were quantified using spectrophotometry (Nanodrop 1000; Thermo
Fisher Scientific, Waltham, MA).
2.4 | Genotyping
2.4.1 | FKBP5
The FKBP5 SNP rs1360780 was genotyped by LGC Genomics
(Hoddesdon, UK) using KASP technology with validated arrays. Geno-
typic distribution of the samples conformed to Hardy–Weinberg pro-
portions (CC = 50.5%, CT = 40.5%, TT = 9.0%; χ21 = .049, p = .820).
Genotype was coded to reflect a dominant model (CC vs. CT/TT; no
risk alleles vs. 1+ risk alleles) as in previously reported studies (Binder
et al., 2008; Klengel et al., 2013).
2.5 | DNA methylation
2.5.1 | Measurement
Extracted DNA (500 ng) was treated with sodium bisulfite using the
EZ-96 methylation kit (Zymo Research, Irvine, CA). polymerase chain
reaction (PCR) amplification of bisulfite-treated DNA was performed
using Sequenom MassCLEAVE tagged primers (designed using the
Sequenom EpiDesigner software, Supporting Information Table S1),
and Qiagen HotStarTaq DNA polymerase, with 35 cycles and an
annealing temperature of 63C. Two regions of interest were assayed
based on previous literatures; first, the promoter region
(chr6:35,695,823-35,696,542 UCSC NCBI37/h19) as examined in
Roberts et al. (2015); second, intron 7 (chr6:35,558,191-35,558,904
UCSC NCBI37/h19) which corresponds to the region defined in Klen-
gel et al., (2013). Further information regarding the genomic location
of these amplicons is provided in the supporting information to this
article (Supporting Information Figures S2 and S3). Percentage DNA
methylation was quantitatively measured using the Sequenom EpiTy-
per system (Sequenom, San Diego, CA). Change in percentage DNA
methylation was calculated for the pre- to post-treatment and pre-
treatment to follow-up periods (later time-point minus earlier time-
point).
2.5.2 | Quality-control
To minimize batch effects, all time-points for each participant were
included in the same plate for bisulfite conversion, PCR amplification
and Sequenom array. Bisulfite conversion and PCR amplification were
both conducted in duplicate and the products pooled at each stage.
Fully methylated and fully unmethylated samples were included as
technical controls. All samples were processed blind to sample identi-
fication. Data generated from the EpiTYPER software were treated
with stringent quality-control analysis. Probes detecting an average
percentage DNA methylation of <5% were excluded from analyses.
Further probes with >15% missingness overall were also excluded.
Finally, only participants with DNA methylation values at pretreat-
ment and posttreatment, follow-up, or both were included in analyses
(n = 110 included in at least one analysis, numbers vary by analysis).
After stringent quality-control, quantitative DNA methylation data
from intron 7 (covering 5 CpG sites) and the promoter region (cover-
ing 2 CpG sites) were used for downstream analysis. Details of the
location of these probes can be found in the Supporting Information
Figures S2 and S3.
2.6 | Gene expression
Gene expression levels for FKBP5 at all time-points were taken from
previously quality-control processed data from whole blood samples
quantified using the Illumina HT-12 v4 BeadChip array (n = 102). Full
details of data preparation and quality-control procedures are
reported elsewhere (Roberts et al., 2017). Briefly, this involved back-
ground correction and filtering based on probe intensity and detection
rates. Probes were then transformed and normalized, and outliers
identified and removed.
2.7 | Ethics statement
This study was conducted in accordance with the principles outlined
by the Declaration of Helsinki. Site-specific trials and the collection of
samples were approved by local Human Ethics and Biosafety Commit-
tees, and all participants provided informed consent. The receipt, stor-
age and analysis of samples were approved by the London-Bentham
NRES Committee and the King's College London Psychiatry, Nursing
and Midwifery Research Ethics Sub-Committee.
3 | ANALYSES
3.1 | Confounding factors
Baseline severity, age, BMI, gender, smoking status, psychoactive
medication status, and other medication status were tested for associ-
ation with percentage reduction in clinical severity and change in
DNA methylation between the time-points tested (Tables 1–3). In
order to control for potential population stratification, the first two
principal components (“PC1” and “PC2”) from genome-wide genotyp-
ing data (details reported elsewhere; Coleman et al., 2016) were also
tested for association with treatment outcome. Variables displaying a
significant association with either treatment outcome or change in
DNA methylation (p < .05) were included as covariates in the relevant
analyses (Tables 1–3).
3.2 | DNA methylation, genotype and outcome
In our primary analyses we tested the association between percentage
improvement in anxiety disorder severity and contemporaneous change
in DNA methylation using linear mixed models. We fitted separate
models focusing on change from baseline to the post-treatment assess-
ment and baseline to follow-up time-points, respectively. In addition, to
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replicate a similar design to our previously reported studies, we also
examined the association between change in DNA methylation at post-
treatment and subsequent treatment outcome at follow-up.
All individuals with available data were included in each model to
maximize sample size. To account for differences between treatment
conditions and potential underlying differences in diagnosis groups,
treatment group was included as a higher order random effect (four
groups, as demonstrated in Supporting Information Figure S1). Fixed
effects of time (days from baseline to post, and days from baseline to
follow-up) and number of sessions were included as covariates, as
well as variables significantly associated with treatment outcome.
Initially, the association between changes in DNA methylation
and treatment outcome were tested (results reported in the Support-
ing Information Table S2). Allele-specific effects of these changes
were subsequently investigated by including a DNA methylation
change by rs1360780 genotype interaction term to the above
models. Separate models were run for each CpG probe. Given the
previously reported allele-specific methylation of a group of CpG
sites in intron 7 (“bin 2” in Klengel et al., 2013), we also combined
CpG probes to give an equivalent group (in this study, data was avail-
able for two of the three CpG sites reported previously).
3.3 | DNA methylation and gene expression
Pairwise correlations were used to examine whether DNA methyla-
tion changes were associated with changes in FKBP5 expression.
3.4 | Multiple testing correction
Results were considered nominally significant at p < .05. A revised
significance threshold was estimated to account for the multiple CpG
probes being tested in this study. The number of independent vari-
ables for DNA methylation changes measured at both post-treatment T
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TABLE 1 Potential confounding variables associated with treatment
outcome
Percentage change in CGI-S severity
Post-treatment Follow-up
Clinical factor R p r p
Baseline severity −.042 .662 .169 .089
Age −.070 .471 .041 .680
BMI .059 .543 −.038 .703
t (df ) p t (df ) p
Gender −.559
(107)
.577 .089 (100) .929
Smoking status .212 (107) .832 −.010
(100)
.992
Psychoactive
medication
4.418
(107)
<.001* 3.150
(100)
<.001*
Other medications 1.308
(107)
.194 1.17 (100) .245
Population
stratification
r p r p
PC1 −.163 .097 −.024 .817
PC2 −.038 .700 .051 .615
N.B *Significant and included as a covariate in analyses.
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and at follow-up (combined) was calculated using Matrix Spectral
Decomposition (MatSpD) to assess the correlations between CpG
probes (Nyholt, 2004). The effective number of independent tests
was estimated at 14.95, when taking shared variance into account. To
account for the additional effect of genotype tested in each interac-
tion analyses, this number was doubled to give 29.9 independent
tests, corresponding to a revised significance threshold of p < .0016.
4 | RESULTS
4.1 | Sample characteristics
From pre- to post-treatment, there was a mean reduction in severity
of 69.5% (range: from 100% to −33%). At follow-up, there was a mean
reduction in severity from baseline of 57.1% (range: from 100% to
−100%). Being on anxiety medication at pretreatment was associated
with treatment outcome (Table 1) and was included as a covariate in
all models (medication = 1, no medication = 0). Principal component
1 (PC1) was associated with change in DNA methylation for both
time-points in Bin 2 (Table 2). Other potential confounders, including
age, medication and smoking histories, were reported to be associated
with change in DNA methylation from pretreatment to follow-up at
particular CpG sites (as detailed in Table 3). These covariates were all
included in the relevant analyses.
4.2 | FKBP5 DNA methylation and outcome
4.2.1 | Intron 7
A significant association with outcome at follow-up was found for
change in DNA methylation during active therapy (from pre- to post-
treatment) at CpG 5 of intron 7 (β = −2.51, p = 3.90 × 10−4; Figure 1,
test statistics in Supporting Information Table S2), which remained
significant after correcting for multiple testing. At this CpG site, those
with a reduction in percentage DNA methylation showed a greater
response to treatment (a higher percentage improvement in CGI
severity), while individuals with an increase in DNA methylation
showed a poorer treatment outcome. Interestingly, change in DNA
methylation at this CpG site across the full course of treatment (pre-
treatment to follow-up) was also nominally associated with outcome
at follow-up, but this effect did not reach the revised level of signifi-
cance (β = −1.65, p = .024, Supporting Information Table S2).
4.2.2 | Promoter
A nominally significant association between outcome at post-treatment
and change in DNA methylation from pre- to post-treatment was found
for CpG 1 of the promoter region (post-treatment: β = 1.74,p = .002,
Supporting Information Table S2), although this significant effect was
not seen for outcome at follow-up.
4.3 | DNA methylation, genotype and outcome
Finally, in order to explore allele-specific effects of DNA methylation,
we tested interactions between rs1360780 and changes in each CpG
site on treatment outcomes (see Table 4). We found no evidence for
allele-specific effects of DNA methylation changes in any of the indi-
vidual CpG sites tested in intron 7 or the previously reported combi-
nation of sites (“bin 2”). However, interestingly, a nominally significant
interaction between rs1360780 genotype and change in DNA methyl-
ation at CpG 2 of the promoter region was detected (β = 2.03,
p = .044). Post-hoc exploration of this effect revealed that in individ-
uals with the “risk” genotype (CT/TT), a decrease in percentage DNA
methylation was associated with a poor response to treatment, while
an increase was associated with a better response (β = 1.73, p = .007;
Figure 2). In contrast, there was no association between DNA methyl-
ation change and treatment outcome for CC genotype individuals
(β = −0.36, p = .640).
4.4 | DNA methylation and gene expression
No correlation was found between changes in DNA methylation at
any CpG site and changes in FKBP5 expression (p >.05 for all probes,
Supporting Information Table S3).
5 | DISCUSSION
In this study we provide novel evidence that DNA methylation
changes at FKBP5 intron 7 are associated with response to exposure-
based cognitive behavior therapy in adults with anxiety disorders. In
our sample, individuals who responded more positively to therapy had
a reduction in DNA methylation at one CpG site of intron 7, while
those who showed a poorer response had little change or an increase
in DNA methylation. This effect remained significant after correcting
for multiple testing. No significant interaction with rs1360780 geno-
type was detected for the CpG sites of intron 7. This finding is inter-
esting as it has previously been demonstrated that a reduction in
DNA methylation at this region is associated with higher levels of
childhood trauma (albeit in an allele-specific manner, Klengel et al.,
2013). It has been suggested that FKBP5 may represent a “differential
susceptibility” gene (Vanzomeren-Dohm, Pitula, Koss, Thomas, & Gun-
nar, 2015), conferring a higher sensitivity to the environment “for
FIGURE 1 Change in DNA methylation from pre- to posttreatment at
CpG 5 of intron 7 and percentage reduction in CGI severity at follow-
up. Percentage reduction in CGI severity at follow-up was significantly
associated with change in % DNA methylation from pre- to post-
treatment (β = −4.26, p = 3.90E-04)
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better or for worse”. Taken with the earlier findings with respect to
child abuse, our results suggest that reduced DNA methylation at
intron 7 may underlie a greater impact of both positive and negative
environments. However, it should be noted that the aforementioned
study of FKBP5 intron 7 DNA methylation and childhood trauma
found no association with recent life events (Klengel et al., 2013), sug-
gesting that FKBP5 demethylation could represent a stable epigenetic
pattern, rather than reflecting rapid environmental changes. Neverthe-
less, in our sample, changes in DNA methylation during the course of
therapy were observed for the majority of individuals, implying that
dynamic changes are possible across the time period measured here.
We also observed a nominally significant effect on outcome of an
interaction between rs1360780 and changes in percentage DNA
methylation at the promoter region of FKBP5. At this CpG site, indi-
viduals with the risk genotype (CT/TT) showed an increase in DNA
methylation associated with better treatment response, and a
decrease in DNA methylation associated with poorer treatment
response. In contrast, no association was seen in individuals homozy-
gous for the C allele. It should be noted that this effect did not survive
correction for multiple testing, likely a result of lack of power due to
the relatively small sample size. Interestingly, we previously reported
allele-specific DNA methylation changes at the same CpG site
(Roberts et al., 2015) were associated with response to CBT in chil-
dren with anxiety disorders. However, in the earlier sample, we
observed the opposite direction of effect, whereby better treatment
response corresponded with an increase in DNA methylation, and
poorer treatment response with decreases in DNA methylation in risk
genotype individuals. These findings suggest that the T allele of
rs1360780 may confer greater variability in biological changes, but
the directionality is not yet clear. It is possible that the relatively small
sample sizes also contribute to the observed imprecision. In addition,
while the current study utilizes a similar design, there were a number
of differences between the two samples. First, all participants in our
previous report were children (mean age 9 years), while the current
sample are adults. Second, all children received CBT, while the adults
received exposure-based therapies. Third, a wide range of anxiety
diagnoses were included in the previous study, whereas the current
study focuses primarily on agoraphobia and panic disorder, and spe-
cific phobias. These cohort and treatment differences may therefore
also account for the lack of continuity between the results.
Intriguingly, the results of this study provide further evidence that
changes at a biological level may be more important for longer term
changes in symptomology. Change in DNA methylation from pre- to
post-treatment showed a strong association with treatment outcome
at follow-up, but no association with treatment outcome at posttreat-
ment. This is in line with previous findings from our team, demonstrat-
ing DNA methylation changes during active treatment in both FKBP5
and SERT genes that were associated with outcome at follow-up
TABLE 4 DNA methylation, rs1360780 and percentage reduction in CGI severity
Post-treatment Follow-up
Pre-Post-treatment, outcome
at follow-up
Region β CI (95%) p β CI (95%) p β CI (95%) p
Intron 7 CpG 1 1.44 −1.40–4.27 .322 −0.36 −3.12–2.40 .798 −0.28 −3.71–3.15 0.875
rs1360780 −0.04 −0.45–0.37 .849 0.11 −0.35–0.58 .638 0.17 −0.29–0.62 0.476
Interaction −1.09 −5.22–3.04 .606 −0.17 −4.42–4.08 .937 1.72 −2.92–6.36 0.467
CpG 2 0.6 −1.35–2.55 .546 0.79 −1.47–3.06 .493 1.95 −0.07–3.96 0.058
rs1360780 −0.06 −0.47–0.34 .764 0.04 −0.42–0.51 .851 0.03 −0.40–0.46 0.877
Interaction −0.29 −3.46–2.89 .860 −0.65 −4.37–3.08 .734 −2.36 −5.62–0.89 0.155
CpG 3 −0.19 −1.10–0.72 .685 −0.93 −1.85–0.01 .049 −0.57 −1.55–0.42 0.258
rs1360780 −0.17 −0.54–0.21 .382 −0.06 −0.46–0.35 .773 −0.11 −0.50–0.28 0.576
Interaction −0.45 −2.09–1.18 .586 0.015 −1.50–1.53 .984 −0.77 −2.36–0.82 0.342
CpG 4 1.57 −1.09–4.24 .248 −1.06 −2.59–0.47 .176 1.29 −1.93–4.51 0.431
rs1360780 −0.13 −0.51–0.25 .503 0.09 −0.35–0.53 .696 −0.06 −0.49–0.37 0.793
Interaction −4.27 −8.87–0.33 .069 1.56 −1.12–4.25 .254 −0.40 −5.55–4.75 0.878
CpG 5 −0.98 −3.27–1.30 .400 −1.93 −3.76–0.09 .040 −4.26 −6.62–1.90 4.10E-04
rs1360780 0.03 −0.37–0.43 .876 0.03 −0.40–0.45 .902 0.2 −0.20–0.60 0.333
Interaction 0.06 −2.90–3.02 .967 0.67 −2.14–3.48 .641 2.73 −0.33–5.80 0.080
Bin 2 1.02 −1.03–3.08 .725 −1.34 −2.92–0.24 .098 −0.71 −3.14–1.72 0.566
rs1360780 −0.13 −0.49–0.22 .468 0.05 −0.38–0.49 .814 −0.02 −0.44–0.40 0.920
Interaction −2.37 −5.76–1.03 .172 0.12 −3.14–3.37 .945 −1.39 −5.28–2.51 0.485
Promoter CpG 1 2.02 0.48–3.55 .010 −0.41 −2.01–1.19 .616 0.79 −1.10–2.67 0.413
rs1360780 −0.06 −0.41–0.29 .728 −0.07 −0.45–0.31 .715 −0.04 −0.43–0.35 0.850
Interaction −0.63 −2.85–1.59 .578 0.88 −1.27–3.02 .423 0.15 −2.45–2.75 0.909
CpG 2 (11) 0.48 −0.75–1.70 .446 −0.65 −1.97–0.68 .340 −0.39 −1.72–0.94 0.564
rs1360780 −0.17 −0.51–0.17 .336 −0.13 −0.50–0.25 .510 −0.13 −0.52–0.25 0.495
Interaction 0.69 −1.11–2.49 .452 1.27 −0.92–3.47 .255 2.03 0.06–4.02 0.044
N.B Values in bold are nominally significant. Highlighted values are significant after correction for multiple testing.
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(Roberts et al., 2014,2015). Additionally, in this study we had data
available for the follow-up time-point, but this did not show a signifi-
cant association with treatment outcome at follow-up. These findings
suggest that epigenetic processes such as DNA methylation may
potentially have a mechanistic role in the efficacy of psychological
therapies. DNA methylation levels, particularly within promoter
regions, are known to have an impact on subsequent gene expression.
However, we found no correlation between observed changes in
DNA methylation at any CpG site and FKBP5 expression, and as such
are not able to make any conclusions regarding the downstream effect
of these processes in our sample––although it should be noted that
DNA methylation and gene expression were determined from sepa-
rate samples.
A number of caveats should be considered when interpreting the
results of this study. First, while the current sample represents one of
the largest reported for epigenetic studies of therapy response, it is
still relatively small. Statistical power estimates (conducted using the
powerreg package in Stata) suggested that the current sample had
around 80% power to detect an effect of a similar magnitude to that
detected for the CpG site in intron 7 with our corrected threshold of
α = 0.0016, though considerably larger samples would be needed to
accurately detect any smaller effects. As such, the study may be
underpowered, particularly to identify significant interactions, and fur-
ther research should aim to utilize larger samples where possible.
However, the inclusion of a follow-up time-point is a particular
strength of the study, and the use of a continuous outcome measure
affords greater power. Second, in this study we have used clinician
rated severity of the treated diagnosis as the primary treatment out-
come. While the CGI is a well-recognized and validated measure, it
only concerns the severity of disorder. Another important aspect of
treatment outcome in clinical psychology and psychiatry, particularly
in fear-related anxiety disorders such as phobias, is reduction in
impairment. Further work in this area should consider changes in
levels of impairment as well as diagnosis severity. However, we have
focused on fear-related anxiety diagnoses as exposure is a key ele-
ment in their treatment, and it is therefore possible that any detect-
able association between epigenetic changes and phenotypic
outcome will be seen at the level of symptoms, rather than acting in a
disorder specific manner. Third, no information was available on early
abuse or historical experiences of trauma in these participants. This is
especially pertinent given the previous research identified early
trauma-related demethylation of FKBP5. Future studies including both
historical data regarding life events and treatment outcomes may have
the potential to fully investigate the potential association between
FKBP5 methylation and both positive and negative environmental
influences. Fourth, the study sample included here contained some
participants currently taking anxiolytic medications. While we
included information regarding medication use at baseline in our sta-
tistical models, it is possible that our results may be confounded by
the effect of medication use on DNA methylation. Finally, the
repeated measures design in a clinical setting necessitates the use of
peripheral samples, in this case whole blood DNA and RNA. Differ-
ences in the collection of such samples, such as time of day, food and
drink intake, seasonality, and sample processing may influence the
subsequent data derived from them. Importantly, tissue-specific DNA
methylation signatures have previously been identified (Davies et al.,
2012), and as such we are unable make any conclusions about the rel-
evance of these findings for any other tissues of interest, namely the
brain. Furthermore, whole blood samples also consist of a heteroge-
neous cell mixture, and no information was available for the propor-
tions of cell types within these samples. As DNA methylation may
vary according to cell type, particularly in relation to the wide age
range of our sample, this may represent an important potential con-
founder contributing to the findings of this study. However, for a
potential biomarker of treatment outcome to have utility in clinical
practice, it must be easily accessed from available sources, and thus
the use of peripheral tissues represents a realistic approach for studies
of this kind.
6 | CONCLUSION
In this study, we demonstrate changes in DNA methylation at
FKBP5 intron 7 associated with reduction in anxiety severity follow-
ing exposure-based CBT. We also observed allele-specific methyla-
tion at the promoter region associated with treatment response,
although this did not reach a revised level of significance when cor-
recting for multiple testing. Nevertheless, the results of this study
add to the growing literature demonstrating the role of biological
processes such as DNA methylation in response to environmental
influences.
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